CR9695A - Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica. - Google Patents

Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica.

Info

Publication number
CR9695A
CR9695A CR9695A CR9695A CR9695A CR 9695 A CR9695 A CR 9695A CR 9695 A CR9695 A CR 9695A CR 9695 A CR9695 A CR 9695A CR 9695 A CR9695 A CR 9695A
Authority
CR
Costa Rica
Prior art keywords
hypnotic agent
action
association
therapeutics
application
Prior art date
Application number
CR9695A
Other languages
English (en)
Inventor
Alain Cuine
Michel Decobert
Dominique Francon
Henry Saunal
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CR9695A publication Critical patent/CR9695A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a la asociacion de un agente hipnotico de duracion de accion corta elegido entre un modulador de los receptores GABA-A, una benzodiazepina, una fenotiazina, un derivado de la melatonina y un agonista de los receptores de la melatonina, y de un agente hipnotico de duracion de accion larga elegido entre un modulador de los receptores GABA-A.
CR9695A 2005-08-19 2008-01-28 Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica. CR9695A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508643A FR2889811B1 (fr) 2005-08-19 2005-08-19 Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.

Publications (1)

Publication Number Publication Date
CR9695A true CR9695A (es) 2008-02-20

Family

ID=36273351

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9695A CR9695A (es) 2005-08-19 2008-01-28 Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica.

Country Status (25)

Country Link
US (2) US20080181943A1 (es)
EP (1) EP1919473B1 (es)
JP (1) JP5215851B2 (es)
KR (1) KR20080039909A (es)
CN (1) CN101267819B (es)
AR (1) AR055123A1 (es)
AU (1) AU2006281334B2 (es)
BR (1) BRPI0614792A2 (es)
CA (1) CA2618212C (es)
CR (1) CR9695A (es)
EA (1) EA014294B1 (es)
EC (1) ECSP088131A (es)
FR (1) FR2889811B1 (es)
HN (1) HN2008000278A (es)
IL (1) IL188823A0 (es)
MA (1) MA29766B1 (es)
MX (1) MX2008002275A (es)
NO (1) NO20081250L (es)
NZ (1) NZ565880A (es)
SG (1) SG165316A1 (es)
TN (1) TNSN08027A1 (es)
TW (1) TW200738238A (es)
UA (1) UA93209C2 (es)
WO (1) WO2007020337A1 (es)
ZA (1) ZA200800968B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
WO2009084023A2 (en) * 2007-10-19 2009-07-09 Glenmark Generics Limited Amorphous ramelteon and process for the preparation thereof
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
US20120108669A1 (en) * 2008-11-13 2012-05-03 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
FR2938534B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Procede de preparation de l'hemifumarate d'eplivanserine
EP2370136A4 (en) * 2008-12-01 2015-12-30 Map Pharmaceuticals Inc INHALATIVE RELEASE PROCEDURES AND DEVICES
WO2010074753A1 (en) * 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
EP2395840B1 (en) 2009-02-13 2020-04-15 Romark Laboratories, L.C. Controlled release pharmaceutical formulations of nitazoxanide
EP2255807A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Method of treating sleep disorders using the combination of eplivanserin and zolpidem
EP2255726A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
WO2012109695A1 (en) * 2011-02-16 2012-08-23 Casal Y Galzov Ramon Ernesto Drug compositions for the treatment of insomnia
US9700548B2 (en) 2011-06-09 2017-07-11 Requis Pharmaceuticals Inc. Antihistamines combined with dietary supplements for improved health
CN102579383A (zh) * 2012-04-09 2012-07-18 南京正科制药有限公司 右佐匹克隆缓释片
CN110604727A (zh) * 2014-02-06 2019-12-24 序列药品有限公司 用于帮助睡眠的组合物及方法
RU2697836C2 (ru) 2015-06-26 2019-08-21 Кореа Юнайтед Фарм. Инк. Комбинированный препарат мозаприда и рабепразола
CN105596313B (zh) * 2016-02-17 2018-06-29 新乡医学院第一附属医院 一种具有反向药理功能的用于治疗失眠的胶囊制剂
CN105997958B (zh) * 2016-07-12 2019-03-26 中国人民解放军白求恩医务士官学校 一种口腔外用制剂及其制备方法
DK3337462T3 (da) * 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf
US11040984B2 (en) * 2016-12-30 2021-06-22 Medshine Discovery Inc. Quinazoline compound for EGFR inhibition
SI3746126T1 (sl) 2018-01-30 2025-01-31 Apnimed, Inc. (Delaware) Postopki in sestavki za zdravljenje spalne apneje ali preprostega smrčanja
GB2594616A (en) 2018-11-21 2021-11-03 Certego Therapeutics Inc Gaboxadol for reducing risk of suicide and rapid relief of depression
EA202192202A1 (ru) * 2019-02-08 2021-11-03 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. Способы и композиции для лечения синдрома обструктивного апноэ, возникающего во сне
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains
CN115919806A (zh) * 2022-12-22 2023-04-07 南京乐韬生物科技有限公司 一种gaba缓释胶囊的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
CN1206996C (zh) * 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder
AU2006265009A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and an antidepressant
RU2008110477A (ru) * 2005-08-19 2009-09-27 Авентис Фармасьютикалз Инк. (Us) Комбинация снотворного и r (+)-а-(2, 3-диметоксифенил)-1-[2-(4-фторфенил)этил]-4-пиперидинметанола и его терапевтическое применение
BRPI0614943A2 (pt) * 2005-08-19 2011-04-26 Aventis Pharma Inc combinação de um agente hipnótico e composto de bisarila e heteroarila substituìdo e aplicação terapêutica da mesma

Also Published As

Publication number Publication date
IL188823A0 (en) 2008-12-29
SG165316A1 (en) 2010-10-28
MA29766B1 (fr) 2008-09-01
FR2889811B1 (fr) 2009-10-09
EP1919473B1 (fr) 2012-12-05
JP5215851B2 (ja) 2013-06-19
US20100291204A1 (en) 2010-11-18
ZA200800968B (en) 2009-04-29
CA2618212C (fr) 2014-03-25
US20080181943A1 (en) 2008-07-31
BRPI0614792A2 (pt) 2011-04-12
EA200800618A1 (ru) 2008-06-30
HN2008000278A (es) 2011-03-30
UA93209C2 (ru) 2011-01-25
NZ565880A (en) 2011-07-29
TNSN08027A1 (en) 2009-07-14
AR055123A1 (es) 2007-08-08
JP2009504713A (ja) 2009-02-05
AU2006281334A1 (en) 2007-02-22
EP1919473A1 (fr) 2008-05-14
AU2006281334B2 (en) 2012-10-18
CN101267819A (zh) 2008-09-17
KR20080039909A (ko) 2008-05-07
ECSP088131A (es) 2008-02-20
NO20081250L (no) 2008-05-13
CA2618212A1 (fr) 2007-02-22
WO2007020337A1 (fr) 2007-02-22
CN101267819B (zh) 2012-05-30
TW200738238A (en) 2007-10-16
FR2889811A1 (fr) 2007-02-23
HK1124541A1 (en) 2009-07-17
EA014294B1 (ru) 2010-10-29
MX2008002275A (es) 2008-03-27

Similar Documents

Publication Publication Date Title
CR9695A (es) Asociacion de un agente hipnotico de duracion de accion larga y un agente hipnotico de duracion de accion corta y su aplicacion en terapeutica.
HN2006007884A (es) Derivados de oxiindol
DE602004028229D1 (de) Prostaglandin analoge als ep4 rezeptor agonisten
ECSP10010724A (es) Compuestos de isoindol 5-sustituidos
PL2119715T3 (pl) Pochodna benzimidazolowa i jej zastosowanie jako agonista receptora AII
AR062875A1 (es) Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos
PA8845901A1 (es) Combinacion de una insulina y un agonista de glp-1
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
CL2008002538A1 (es) Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
DK1813614T3 (da) Cytotoksiske midler, der omfatter nye tomaymycinderivater
ECSP077236A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
AR063640A1 (es) Anticuerpos agonistas de trkb y usos de los mismos
AR059423A1 (es) Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables
HN2007000437A (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
HN2006035237A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
ECSP099822A (es) Derivados de guanina policiclicos y sus métodos de uso
CL2009001804A1 (es) Uso de un copolimero de vinilamina-vinilformamida y un portador para preparar una composicion destinada a fortalecer las fibras queratinosas.
CL2012001352A1 (es) Compuestos heterocíclicos derivados de amina, moduladores del receptor s1p; composición farmacéutica que los comprende; uso para tratar enfermedades oculares, vasculares sistémicas inflamatorias, autoinmunitarias e inmunosupresión, cicatrización y dolor entre otras.
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
MA28580B1 (fr) 3-(4-hétéroarylcyclohexylamino) cyclopentanecarboxamides servant de modulateurs de récepteurs de chimiokines
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
CL2008001810A1 (es) Compuestos derivados de espiroindolinas, moduladores de receptores de quimiocinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar aterosclerosis, dolor inflamatorio, influenza, sindrome metabolico, entre otras enfermedades.
ATE427299T1 (de) Indol-2-carboxamidin-derivate als antagonisten der nmda-rezeptoren

Legal Events

Date Code Title Description
FC Refusal